A Phase 1 clinical trial to evaluate its safety, tolerability, and immunogenicity of AV-1980R
Latest Information Update: 07 Dec 2021
At a glance
- Drugs AV-1980R (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- 07 Dec 2021 New trial record
- 22 Nov 2021 According to an Institute for Molecular Medicine media release, the company has recently completed using the NIA funding and is currently on track for this phase 1 study.